AI-generated analysis. Always verify with the original filing.
Tenax Therapeutics, Inc. filed an 8-K on March 10, 2026, including Exhibit 99.1 press release under Item 2.02, which is not deemed 'filed' for purposes of Section 18 of the Exchange Act. The filing contains no explicit disclosure details on results of operations or other events.
Event Type
Disclosure
Mandatory
Variant
8-K
(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or other
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated March 10, 2026. 104 Cover Page Interactive Data File (embedded